ANEB Anebulo Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-09 16:00
Why ANEB matters now
Anebulo Pharmaceuticals, Inc. (ANEB) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.34 with +0.00% on the session and $13.7M in market capitalization; recent performance reads 1-month -15.22% and YTD -61.39%.
The latest financial table shown here is Q2 2026, with revenue of $0.00, net income of $-2.0M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -36.7%.
Additional event context on this page matters because analyst consensus is Hold with a median target of $6.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.02
P/S
0.00
EV/EBITDA
-0.93
DCF Value
$0.34
FCF Yield
-36.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-74.6%
ROA
-84.7%
ROIC
-102.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-2.0M | $-0.05 |
| Q1 2026 | $0.00 | $-2.2M | $-0.05 |
| Q4 2025 | $0.00 | $-2.1M | $-0.05 |
| FY 2025 | $0.00 | $-8.5M | $-0.25 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Related Stocks
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-1.87
Anebulo Pharmaceuticals, Inc. is a biotechnology firm currently in the clinical trial phase, committed to devising and introducing treatments for individuals affected by severe cannabinoid poisoning and various forms of substance dependency. Its leading experimental drug, ANEB-001, is a small molecule engineered to counteract cannabinoid receptors, specifically targeting both cannabinoid intoxication and overdose. The company was founded in 2020 and maintains its headquarters in Lakeway, Texas.